AbCellera Biologics Inc vs Nasdaq100 ETF — how do they compare? AbCellera Biologics Inc trades at $10.05 (market cap $2.99B), while Nasdaq100 ETF trades at $723.88. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Nasdaq100 ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | QQQ | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | — |
52-Week High | $9.76 | $746.16 |
52-Week Low | $2.78 | $558.34 |
Enterprise Value | $2.58B | — |
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
QQQ trades at $725.43, up 0.64% with a bullish technical signal from moving averages. The ETF shows strong institutional interest with Ferguson Shapiro LLC increasing its position by 2,685.7% according to SEC filings. Recent news highlights Nasdaq's tech-led rally potential in H2 2026, with momentum and Fed liquidity supporting further upside according to Zacks Investment Research.
Outlook remains positive given historical performance and current technical strength, though RSI levels suggest potential near-term consolidation. Key risks include ETF expense ratios and market volatility, while opportunities lie in continued tech sector leadership and institutional accumulation patterns.
Trailing returns across standard periods
Latest headlines on both assets
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →